Membership of the Advanced Therapies Advisory Group includes representatives from AusBiotech and Medicines Australia member companies. The advisory group’s focus includes policy development, advocacy and industry enablement specific to the cell and gene therapy sector in Australia.

Members

• Simon Cool (Chair) – Chief Executive Officer, SMART CRC
• Dominic Fernandez – Scientific Lead, Cell Therapy and Immunotherapy, Epworth Healthcare
• Gretchen Poortinga – Program Operations Director, Centre of Excellence in Cellular Immunotherapy, Peter MacCallum Cancer Centre
• Shanny Dyer – Director, Rheumagen Australia
• Stephen Thompson – Chief Executive Director, Viral Vector Manufacturing Facility
• Jasmine Oberwalleney – APAC CAR-T Launch Director, Miltenyi Biotec Australia
• Cecile Francis – Director of Partnerships, UniQuest
• Umesh Nair – Major Account Manager, Merck Life Science
• Helen Dodds – Clinical Trials Startup Lead, Sanofi
• Oona Reardon – Director, Pulse Economics Consulting
• Warwick Shaw – Market Access Cell & Gene Therapies, Johnson & Johnson
• Rebecca Stratford – Head of Market Access, Oncology, AstraZeneca
• Dylan Jones – Country Head of Value & Access, Novartis
• Kathy Gibson – Executive Director, Strategic Medical Engagement, Eli Lilly
• Brendon Boot – Chief Executive Officer, Skin2Neuron

For more information about the Advanced Therapies Advisory Group, please contact Stephen Richardson ([email protected]).